Literature DB >> 16280097

Comparative study of anti-inflammatory and ulcerogenic activities of different cyclo-oxygenase inhibitors.

Alessandra Gambero1, Tagliane Liza Becker, Andréa Silva Zago, Andréa Fermino de Oliveira, José Pedrazzoli.   

Abstract

The aim of the present work was to study the in vivo anti-inflammatory activity of six NSAIDs, ibuprofen, diclofenac, nimesulide, meloxicam, celecoxib and rofecoxib, using the rat air-pouch model of inflammation to characterize the ability of these drugs to induce gastric damage and PGE(2) inhibition. Selective compounds were observed to have no ulcerogenic properties at anti-inflammatory doses; however, these drugs were weaker inhibitors of several inflammatory aspects such as cell influx and exudate formation. In contrast, the non-selective and preferential compounds present anti-inflammatory properties at lower doses than presented by selective drugs. At anti-inflammatory doses, only meloxicam and ibuprofen produced gastric damage and inhibition of PGE(2) synthesis, suggesting that ulcerogenic properties of NSAIDs cannot be predicted by their selectivity index, since meloxicam demonstrates ulcerogenic properties despite its preferential profile.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16280097     DOI: 10.1163/156856005774649377

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   4.473


  34 in total

1.  Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).

Authors:  T D Penning; J J Talley; S R Bertenshaw; J S Carter; P W Collins; S Docter; M J Graneto; L F Lee; J W Malecha; J M Miyashiro; R S Rogers; D J Rogier; S S Yu; E G Burton; J N Cogburn; S A Gregory; C M Koboldt; W E Perkins; K Seibert; A W Veenhuizen; Y Y Zhang; P C Isakson
Journal:  J Med Chem       Date:  1997-04-25       Impact factor: 7.446

Review 2.  Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs).

Authors:  J L Wallace
Journal:  Am J Med       Date:  1999-12-13       Impact factor: 4.965

3.  Current problems with non-specific COX inhibitors.

Authors:  P McGettigan; D Henry
Journal:  Curr Pharm Des       Date:  2000-11       Impact factor: 3.116

4.  Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation.

Authors:  J L Wallace; K Chapman; W McKnight
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

5.  Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.

Authors:  C C Chan; S Boyce; C Brideau; S Charleson; W Cromlish; D Ethier; J Evans; A W Ford-Hutchinson; M J Forrest; J Y Gauthier; R Gordon; M Gresser; J Guay; S Kargman; B Kennedy; Y Leblanc; S Leger; J Mancini; G P O'Neill; M Ouellet; D Patrick; M D Percival; H Perrier; P Prasit; I Rodger
Journal:  J Pharmacol Exp Ther       Date:  1999-08       Impact factor: 4.030

6.  Prevention of cytokine-induced changes in leukocyte adhesion receptors by nonsteroidal antiinflammatory drugs from the oxicam family.

Authors:  R García-Vicuña; F Díaz-González; I González-Alvaro; M A del Pozo; F Mollinedo; C Cabañas; R González-Amaro; F Sánchez-Madrid
Journal:  Arthritis Rheum       Date:  1997-01

7.  Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use.

Authors:  Hubert Blain; Christelle Boileau; Françoise Lapicque; Emmanuelle Nédélec; Damien Loeuille; Cécile Guillaume; Alain Gaucher; Claude Jeandel; Patrick Netter; Jean-Yves Jouzeau
Journal:  Br J Clin Pharmacol       Date:  2002-03       Impact factor: 4.335

8.  Inhibition of gastric secretion by a water extract from Baccharis triptera, Mart.

Authors:  M T Gamberini; L A Skorupa; C Souccar; A J Lapa
Journal:  Mem Inst Oswaldo Cruz       Date:  1991       Impact factor: 2.743

9.  Ibuprofen inhibits pyrogen-dependent expression of VCAM-1 and ICAM-1 on human endothelial cells.

Authors:  S Kapiotis; G Sengoelge; W R Sperr; M Baghestanian; P Quehenberger; D Bevec; S R Li; E J Menzel; A Mühl; D Zapolska; I Virgolini; P Valent; W Speiser
Journal:  Life Sci       Date:  1996       Impact factor: 5.037

10.  Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation.

Authors:  R M Pinheiro; J B Calixto
Journal:  Inflamm Res       Date:  2002-12       Impact factor: 4.575

View more
  3 in total

1.  Effect of different cyclooxygenase inhibitors on gastric adaptive cytoprotection induced by 20% ethanol.

Authors:  Alessandra Gambero; Marta Maróstica; Tagliane Liza Becker; José Pedrazzoli
Journal:  Dig Dis Sci       Date:  2007-01-17       Impact factor: 3.199

2.  An overview of clinical pharmacology of Ibuprofen.

Authors:  Rabia Bushra; Nousheen Aslam
Journal:  Oman Med J       Date:  2010-07

3.  Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes.

Authors:  Chang-Keun Cho; Hye-Jung Park; Pureum Kang; Sungmin Moon; Yun Jeong Lee; Jung-Woo Bae; Choon-Gon Jang; Seok-Yong Lee
Journal:  Arch Pharm Res       Date:  2021-11-22       Impact factor: 4.946

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.